Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment

NCT01721837 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01721837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01721837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
October 31, 2012
Completion date
June 30, 2013
Enrollment
4,340 (actual)
Sites
1,616

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation